Table 3 Effect of growth hormone (GH) treatment on 21 patients
From: Genetic subtypes and phenotypic characteristics of 110 patients with Prader-Willi syndrome
Parameters | Before GH treatment | After GH treatment | Reference ranges |
|---|---|---|---|
General information | |||
 Case evaluated | n = 21 | / | |
 Sex: male/female | 14/7 | / | |
 Genetic subtype: UPD/Del | 3/18 | / | |
 Median age at onset (range, years) | 2.1 (0.9–4.8) | / | |
Anthropometry | |||
 Length/height SDS |  – 1.32 ± 1.19 |  − 0.43 ± 0.68* | / |
 Body weight SDS | 0.20 ± 1.76 | 0.34 ± 1.53 | / |
 BMI SDS | 0.75 ± 1.91 | 1.03 ± 1.65 | / |
Laborotory | |||
 Insulin-like growth factor I (IGF-I) SDS |  − 1.97 ± 1.12 |  − 0.45 ± 0.48* | / |
 Thyroid stimulating hormone (TSH, μIU/mL) | 1.80 ± 0.86 | 1.96 ± 0.97 | 0.30–4.80 |
 Free thyroxine (fT4, pmol/L) | 13.02 ± 1.37 | 11.58 ± 2.04 | 9.01–19.05 |
 Free triiodothyronine (fT3, pmol/L) | 5.52 ± 0.59 | 5.15 ± 0.80 | 2.43–6.01 |
 Fasting glucose (mg/dL) | 4.96 ± 0.63 | 4.72 ± 0.77 | 3.9–6.11 |
 Fasting insulin (μIU/mL) | 19.43 ± 8.70 | 17.43 ± 6.24 | 3.9–25.00 |
 Total triglyceride (mmol/L) | 0.96 ± 0.40 | 1.14 ± 0.55 | 0.4–1.69 |
 Total cholesterol (mmol/L) | 4.84 ± 1.38 | 5.02 ± 1.82 | 3.36–5.69 |
 Low density lipoprotein (LDL, mmol/L) | 3.07 ± 1.34 | 3.88 ± 1.07 |  < 3.37 |